Related Experiment Video
Updated: Jun 16, 2025

07:07
A Melanoma Patient-Derived Xenograft Model
Published on: May 20, 2019
12.3K
Single-Cell Transcriptomic Landscape Deciphers Intratumoral Heterogeneity and Subtypes of Acral and Mucosal Melanomas
Yunyan Li1,2, Ziyang Cui3, Xiaole Song4,5
1Skin Disease Research Institute, The Second Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, China.
Summary
This study reveals key differences in acral melanoma (AM) and mucosal melanoma (MM) by analyzing their cellular makeup and microenvironments. Findings identify new therapeutic targets for these aggressive skin cancers.
Area of Science:
- Oncology
- Genomics
- Immunology
Background:
- Acral melanoma (AM) and mucosal melanoma (MM) are rare but aggressive subtypes of cutaneous melanoma.
- Understanding their distinct intratumoral and microenvironmental heterogeneity is crucial for developing effective therapies.
Purpose of the Study:
- To delineate the distinct cellular compositions and evolutionary trajectories of AM and MM.
- To identify subtype-specific therapeutic strategies for these melanomas.
Main Methods:
- Single-cell RNA sequencing and whole-exome sequencing were performed on 42 melanoma samples (28 AM, 11 MM).
- Functional assays including transwell migration, co-culture systems, and xenograft models were utilized for validation.
- Tumor and stromal cells were profiled to analyze cellular and molecular characteristics.
Main Results:
- MM showed high epithelial-to-mesenchymal transition potential, neutrophil infiltration, and CXCL3+ macrophages.
- AM was enriched with PI16+ cancer-associated fibroblasts and TIGIT+ regulatory T cells.
- MM subtypes were identified: antigen-presenting (favorable outcome) and proliferative (recurrence).
- BRAF/NRAS mutations were linked to ALDOA+ stem-like cells, and prostaglandin D2 synthetase emerged as a therapeutic target.
Conclusions:
- This study provides a comprehensive comparison of AM and MM, revealing subtype-specific stromal-immune interactions.
- Actionable targets like TIGIT in AM and CXCL3+ macrophages in MM were highlighted.
- A framework for precision therapies, biomarker-driven trials, and risk stratification was proposed to improve outcomes.

